Dermatology · Boston, MA
NPI
1073503603
Since 2005
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
330 Brookline Ave
Boston, MA, 02215
Phone (617) 667-3753
Groups this clinician bills Medicare through
Medicare paid, 2024
$6,187
147 services
Medicare patients, 2024
41
Average age 66
Drug cost, 2024
$3.0M
297 prescriptions
Company payments, 2025
$273K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alexandra B Kimball was code 99214 (office e&m - established), 51 times for 31 patients. In total Alexandra B Kimball billed 147 services in 13 codes, and Medicare paid $6,187.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-05-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 51 | 31 | $70.13 | $3,577 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 38 | 27 | $13.07 | $497 |
| 99213 Office E&M - Established | Facility | 13 | 12 | $32.90 | $428 |
By year: 2022 $6,792 for 140 services; 2023 $6,498 for 118 services; 2024 $6,187 for 147 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alexandra B Kimball prescribed most often to Medicare patients was Humira(Cf) Pen (Adalimumab), with 47 prescriptions and refills. In total Alexandra B Kimball wrote 297 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Humira(Cf) Pen Adalimumab | 47 | 47 | Under 11 | $1.2M |
| Bimzelx Autoinjector Bimekizumab-Bkzx | 32 | 32 | Under 11 | $507K |
| Cosentyx Sensoready (2 Pens) Secukinumab | 29 | 29 | Under 11 | $357K |
| Spironolactone Generic | 18 | 42 | Under 11 | $414 |
| Methotrexate Methotrexate Sodium | 17 | 27 | Under 11 | $101 |
| Skyrizi Pen Risankizumab-Rzaa | 14 | 29 | Under 11 | $282K |
| Rinvoq Upadacitinib | 13 | 13 | Under 11 | $81K |
| Remicade Infliximab | 13 | 13 | Under 11 | $131K |
| Dupixent Pen Dupilumab | 12 | 12 | Under 11 | $87K |
Brand drugs: 203 claims; generic drugs: 94 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alexandra B Kimball $273K ($261K in general payments such as food, travel and fees and $13K for research) from 13 companies. The largest payer was Almirall LLC with $211K.
| Company | Payments | Amount |
|---|---|---|
| Almirall LLC | 27 | $211K |
| Eli Lilly and Company LLY | 7 | $17K |
| Genzyme Corporation SNY | 5 | $9,623 |
| Regeneron Pharmaceuticals, Inc. REGN | 9 | $9,068 |
| Pfizer Inc. PFE | 6 | $6,637 |
| Ucb Sa UCB.BR | 2 | $6,543 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $6,482 |
| Incyte Corporation INCY | 10 | $4,763 |
| Novartis Pharma AG NVS | 1 | $1,200 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $875 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.